31842 Federal Register / Vol. 72, No. 110 / Friday, June 8, 2007 / Notices 

drug products for use in the treatment 

of arthritis, rheumatism, and related 

diseases. 

7. Cardiovascular and Renal Drugs 

Advisory Committee 

Reviews and evaluates available data 

concerning the safety and effectiveness 

of marketed and investigational human 

drug products for use in the treatment 

of cardiovascular and renal disorders. 

8. Dermatologic and Ophthalmic Drugs 

Advisory Committee 

Reviews and evaluates available data 

concerning the safety and effectiveness 

of marketed and investigational human 

drug products for use in the treatment 

of dermatologic and ophthalmic 

disorders. 

9. Drug Safety and Risk Management 

Advisory Committee 

Advises the Commissioner of Food 

and Drugs (the Commissioner) regarding 

the scientific and medical evaluation of 

all information gathered by the 

Department of Health and Human 

Services and the Department of Justice 

with the regard to safety, efficacy, and 

abuse potential, risk management, risk 

communication, and quantitative 

evaluation of spontaneous reports, and 

recommends actions to be taken by FDA 

with regard to marketing, investigation, 

and control of such drugs or other 

substances. 

10. Endocrinologic and Metabolic Drugs 

Advisory Committee 

Reviews and evaluates available data 

concerning the safety and effectiveness 

of marketed and investigational human 

drug products for use in the treatment 

of endocrine and metabolic disorders. 

11. Gastrointestinal Drugs Advisory 

Committee 

Reviews and evaluates available data 

concerning the safety and effectiveness 

of marketed and investigational human 

drug products for use in the treatment 

of gastrointestinal disorders. 

12. Nonprescription Drugs Advisory 

Committee 

Reviews and evaluates available data 

concerning the safety and effectiveness 

of over-the-counter (nonprescription) 

human drug products for use in the 

treatment of a broad spectrum of human 

symptoms and diseases. 

13. Oncologic Drugs Advisory 

Committee 

Reviews and evaluates available data 

concerning the safety and effectiveness 

of marketed and investigational human 

drug products for use in the treatment 

of cancer. 

14. Peripheral and Central Nervous 

System Drugs Advisory Committee 

Reviews and evaluates available data 

concerning the safety and effectiveness 

of marketed and investigational human 

drug products for use in the treatment 

of neurologic diseases. 

15. Psychopharmacologic Drugs 

Advisory Committee 

Reviews and evaluates available data 

concerning the safety and effectiveness 

of marketed and investigational human 

drug products for use in the practice of 

psychiatry and related fields. 

16. Pulmonary-Allergy Drugs Advisory 

Committee 

Reviews and evaluates available data 

concerning the safety and effectiveness 

of marketed and investigational human 

drug products for use in the treatment 

of pulmonary disease and diseases with 

allergic and/or immunologic 

mechanisms. 

II. Selection Procedure 

Any industry organization interested 

in participating in the selection of an 

appropriate nonvoting member to 

represent industry interests should send 

a letter stating that interest to the FDA 

contact (see FOR FURTHER INFORMATION

CONTACT) within 30 days of publication 

of this document (see DATES). Within the 

subsequent 30 days, FDA will send a 

letter to each organization that has 

expressed and interest, attaching a 

complete list of all such organizations; 

and a list of all nominees along with 

their current resumes. The letter will 

also state that it is the responsibility of 

the interested organizations to confer 

with one another and to select a 

candidate, within 60 days after the 

receipt of the FDA letter, to serve as the 

nonvoting member to represent industry 

interests for a particular committee. The 

interested organizations are not bound 

by the list of nominees in selecting a 

candidate. However, if no individual is 

selected within 60 days, the 

Commissioner will select the nonvoting 

member to represent industry interests. 

III. Application Procedure 

Individuals may self nominate and/or 

an organization may nominate one or 

more individuals to serve as a nonvoting 

industry representative. A current 

curriculum vitae and the name of the 

committee of interest should be sent to 

the FDA contact person (see FOR

FURTHER INFORMATION CONTACT) within 

30 days (see DATES). FDA will forward 

all nominations to the organizations 

expressing interest in participating in 

the selection process for that committee. 

(Persons who nominate themselves as 

nonvoting industry representatives will 

not participate in the selection process.) 

FDA has a special interest in ensuring 

that women, minority groups, 

individuals with physical disabilities, 

and small businesses are adequately 

represented on its advisory committees, 

and therefore, encourages nominations 

for appropriately qualified candidates 

from these groups. Specifically, in this 

document, nominations for nonvoting 

representatives of industry interests are 

encouraged from the drug 

manufacturing industry. 

This notice is issued under the 

Federal Advisory Committee Act (5 

U.S.C. app. 2) and 21 CFR part 14, 

relating to advisory committees. 

Dated: May 28, 2007. 

Randall W. Lutter, 

Associate Commissioner for Policy and 

Planning. 

[FR Doc. E7–11065 Filed 6–7–07; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Agency Information Collection 

Activities: Proposed Collection; 

Comment Request 

In compliance with section 

3506(c)(2)(A) of the Paperwork 

Reduction Act of 1995 concerning 

opportunity for public comment on 

proposed collections of information, the 

Substance Abuse and Mental Health 

Services Administration (SAMHSA) 

will publish periodic summaries of 

proposed projects. To request more 

information on the proposed projects or 

to obtain a copy of the information 

collection plans, call the SAMHSA 

Reports Clearance Officer on (240) 276–

1243. 

Comments are invited on: (a) Whether 

the proposed collections of information 

are necessary for the proper 

performance of the functions of the 

agency, including whether the 

information shall have practical utility; 

(b) the accuracy of the agency’s estimate 

of the burden of the proposed collection 

of information; (c) ways to enhance the 

quality, utility, and clarity of the 

information to be collected; and (d) 

ways to minimize the burden of the 

collection of information on 

respondents, including through the use 

of automated collection techniques or 

other forms of information technology. 

Proposed Project: Participant 

Feedback on Training Under the 

Cooperative Agreement for Mental 


pwalker on PROD1PC71 with NOTICES
Federal Register / Vol. 72, No. 110 / Friday, June 8, 2007 / Notices 31843 

Health Care Provider Education in HIV/ 

AIDS Program (OMB No. 0930–0195)—

Extension 

The Substance Abuse and Mental 

Health Services Administration’s 

(SAMHSA) Center for Mental Health 

Services (CMHS) intends to continue to 

conduct a multi-site assessment for the 

Mental Health Care Provider Education 

in HIV/AIDS Program. These education 

programs are designed to disseminate 

knowledge of the psychological and 

neuropsychiatric sequelae of HIV/AIDS 

to both traditional (e.g., psychiatrists, 

psychologists, nurses, primary care 

physicians, medical students, and social 

workers) and non-traditional (e.g., 

clergy, and alternative health care 

workers) first-line providers of mental 

health services, in particular to 

providers in minority communities. 

The multi-site assessment is designed 

to assess the effectiveness of particular 

training curricula, document the 

integrity of training delivery formats, 

and assess the effectiveness of the 

various training delivery formats. 

Analyses will assist CMHS in 

documenting the numbers and types of 

traditional and non-traditional mental 

health providers accessing training; the 

content, nature and types of training 

participants receive; and the extent to 

which trainees experience knowledge, 

skill and attitude gains/changes as a 

result of training attendance. The multisite data collection design uses a twotiered data collection and analytic 

strategy to collect information on (1) the 

organization and delivery of training, 

and (2) the impact of training on 

participant’s knowledge, skills and 

abilities. 

Information about the organization 

and delivery of training will be 

collected from trainers and staff, hence 

there is no respondent burden. All 

training participants will be asked to 

complete a brief feedback form at the 

end of the training session. CMHS 

anticipates funding 10 education sites 

for the Mental Health Care Provider 

Education in HIV/AIDS Program. The 

annual burden estimates for this activity 

are shown below: 

Form 

Responses 

per respondent 

Estimated number 

of respondents 

× 10 sites) 

Hours per 

response Total hours 

Session Report Form ............................................................................................. 1 60 × 10 = 600 0.080 48 

Participant Feedback Form (General Education) .................................................. 1 500 × 10 = 5000 0.167 835 

Neuropsychiatric Participant Feedback Form ....................................................... 1 160 × 10 = 1600 0.167 267 

Non Physician Neuropsychiatric Participant Feedback Form ............................... 1 240 × 10 = 2400 0.167 401 

Adherence Participant Feedback Form ................................................................. 1 100 × 10 = 1000 0.167 167 

Ethics Participant Feedback Form ........................................................................ 1 200 × 10 = 2000 0.167 125 

Total ................................................................................................................ .................... 12,600 .................... 1,843 

Send comments to Summer King, 

SAMHSA Reports Clearance Officer, 

Room 7–1044, One Choke Cherry Road, 

Rockville, MD 20857 and e-mail her a 

copy at summer.king@samhsa.hhs.gov. 

Written comments should be received 

within 60 days of this notice. 

Dated: May 30, 2007. 

Elaine Parry, 

Acting Director, Office of Program Services. 

[FR Doc. 07–2871 Filed 6–7–07; 8:45 am] 

BILLING CODE 4162–20–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Agency Information Collection 

Activities: Proposed Collection; 

Comment Request 

In compliance with section 

3506(c)(2)(A) of the Paperwork 

Reduction Act of 1995 concerning 

opportunity for public comment on 

proposed collections of information, the 

Substance Abuse and Mental Health 

Services Administration (SAMHSA) 

will publish periodic summaries of 

proposed projects. To request more 

information on the proposed projects or 

to obtain a copy of the information 

collection plans, call the SAMHSA 

Reports Clearance Officer on (240) 276–

1243. 

Comments are invited on: (a) Whether 

the proposed collections of information 

are necessary for the proper 

performance of the functions of the 

agency, including whether the 

information shall have practical utility; 

(b) the accuracy of the agency’s estimate 

of the burden of the proposed collection 

of information; (c) ways to enhance the 

quality, utility, and clarity of the 

information to be collected; and (d) 

ways to minimize the burden of the 

collection of information on 

respondents, including through the use 

of automated collection techniques or 

other forms of information technology. 

Proposed Project: 2007 National Survey 

of Mental Health Treatment Facilities 

(NSMHTF) (OMB No. 0930–0119)—

Revision 

The Substance Abuse and Mental 

Health Services Administration’s 

(SAMHSA) Center for Mental Health 

Services (CMHS) will conduct a 2007 

NSMHTF. This national survey 

represents a re-design of the biennial 

Survey of Mental Health Organizations 

(SMHO) last conducted in 2004 under 

OMB No. 0930–0119. Instead of 

surveying each mental health 

organization as a whole, the 2007 

NSMHTF will survey all of the mental 

health treatment locations. These 

separate mental health service locations 

are called facilities, in contrast to 

mental health organizations, which may 

include multiple facilities (service 

locations). This survey will be (a) a 100 

percent enumeration of all known 

mental health treatment facilities 

nationwide, (b) more consumer-oriented 

in describing services available at each 

facility location, and (c) patterned after 

SAMHSA’s Office of Applied Studies 

National Survey of Substance Abuse 

Treatment Services (OMB No. 0930–

0106). 

The 2007 NSMHTF will utilize one 

questionnaire for all mental health 

treatment facility types including 

hospitals, residential treatment centers 

and outpatient clinics. The information 

collected will include intake telephone 

numbers for services, types of services 

offered and acceptable forms of 

payment, emergency hotline numbers, 

facility caseload, and facility bed 

counts, if applicable. All treatment 

facilities will be contacted by telephone 

prior to the mailing to verify their 

eligibility, and facility type. 

The resulting database will be used to 

provide both state and national 

estimates of facility types and their 

patient caseloads. Information from the 

2007 survey will also be used to update 

the National Mental Health Information 

Center’s facility locator for consumers. 

In addition, data derived from the 


pwalker on PROD1PC71 with NOTICES